BC Innovations | Jun 29, 2017
Product R&D

Drop the MIC

Two start-ups have joined the wave of companies harnessing NK cell biology to generate new immunotherapies for cancer by focusing on the relatively unexplored ligands for the NK cell receptor NKG2D . Having laid low for...
BC Innovations | Oct 15, 2015
Distillery Therapeutics

Therapeutics: Insulin-regulated aminopeptidase (IRAP); somatostatin receptor 2 (SSTR2)

Neurology INDICATION: Seizures In vitro and rat studies suggest IRAP antagonists could help treat limbic seizures. In rat hippocampal neurons, an antagonistic ligand for the vesicular trafficking molecule IRAP or IRAP knockout increased recycling and...
BC Innovations | Jan 16, 2014
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Endoplasmic reticulum aminopeptidase 1 (ERAP1; ARTS1; ERAAP); ERAP2; insulin-regulated aminopeptidase (IRAP) In vitro and mouse studies identified inhibitors of ERAP1, ERAP2 and IRAP that...
BC Week In Review | Nov 5, 2012
Company News

Servier, Florey Institute of Neuroscience and Mental Health, Monash University, St. Vincent's Institute of Medical Research neurology news

Servier will provide funding to the institutes to develop insulin-regulated aminopeptidase (IRAP) inhibitors to treat Alzheimer's disease (AD). The researchers will use the funding to determine exactly how IRAP inhibitors work to reduce amyloid plaque...
BC Week In Review | Aug 27, 2001
Company News

Gemin X Biotechnologies Inc. other research news

Gemin X received a C$350,000 (US$226,730) Industrial Research Assistance Program (IRAP) grant from the National Research Council of Canada (NRC) to fund antiviral research using apoptosis to target and destroy cells latently infected with viruses....
BC Week In Review | Sep 6, 1994
Company News

Procyon other research news

The London, Ontario, company received a grant under the Canadian National Research Council's Industrial Research Assistance Program (IRAP) to develop a prostate diagnostic test. IRAP will match Procyon's investment, up to C$200,000, over an 18-month...
BC Week In Review | Jun 13, 1994
Clinical News

Modified retrovirus: The trial will begin on final approval from the FDA.

University of Pittsburg Medical Center   Product: Modified retrovirus bearing the gene for interleukin-1 receptor antagonist protein (IRAP)   Indication: Rheumatoid arthritis   Status: University researchers received approval from the Recombinant DNA Advisory Committee to...
BC Week In Review | Nov 22, 1993
Clinical News

Human interleukin 1-receptor antagonist protein data

Company researchers and colleagues introduced the gene for IRAP into cells from the synovial lining of joints and injected the transformed synovial cells directly into the knee joints of rabbits, with successful expression of the...
Items per page:
1 - 8 of 8